Management

Blend is building a team of innovative and successful drug developers whose deep collective experience spans drug discovery, research, and development at leading biotechnology and pharmaceutical companies.

Richard Wooster

Richard Wooster is Chief Scientific Officer at Blend and has more than two decades of experience in cancer genetics and pharmaceutical drug discovery and development. Previously, he was Vice President and Head of the Cancer Metabolism Discovery Performance Unit in Oncology at GlaxoSmithKline. In this role, he led the evaluation of the metabolic pathways that are deregulated in cancer, led the PI3K portfolio of inhibitors in Oncology at GSK and was responsible for the clinical evaluation of the novel antimitotic kinase inhibitors to PLK and CENPE. Before this, Dr. Wooster led the translational medicine group in Oncology at GSK and worked on Tykerb, Mekinist and Tafinlar. During his academic career, Dr. Wooster discovered the breast cancer susceptibility gene BRCA2, was one of the founders of the Cancer Genome Project at the Welcome Trust Sanger Institute where, among many achievements, mutations in BRAF were first discovered and he developed the COSMIC mutation database and website. He has more than 100 peer-reviewed articles and papers in scientific journals. Dr. Wooster has a First Class BSc in Biochemistry and a PhD in drug metabolizing enzymes, both from the University of Dundee, Scotland.

Craig Dunbar

Craig Dunbar is Vice President of Product Development at Blend, with more than 15 years of experience in drug product development, formulation design, process development, and analytical chemistry. Previously, he was Senior Director of Formulation Development at Vertex Pharmaceuticals, where he contributed to the development and approval of Incivek™ and Kalydeco™. Prior to that, Dr. Dunbar served in multiple leadership roles at Alkermes, including Director of Analytical Development and Director of Aerosol Science. Dr. Dunbar received a B.Eng. in Mechanical Engineering from the University of Manchester (UK) and a Ph.D. in Mechanical Engineering from the University of Manchester Institute of Science and Technology. He conducted postdoctoral studies at the University of North Carolina and GlaxoSmithKline.

Mark Bilodeau

Mark Bilodeau is Vice President of Medicinal Chemistry at Blend, with more than 16 years of experience in medicinal chemistry and drug discovery. Previously, he was Senior Director of Medicinal Chemistry at Merck & Co. Inc., where he developed a broad background in drug discovery for the oncology, pain, neuroscience, ophthalmology, and cardiovascular therapeutic areas. While at Merck, Dr. Bilodeau was an inventor and team leader on seven molecules that advanced into clinical testing and also led a development team that brought one molecule from discovery through Phase I clinical testing. Dr. Bilodeau received a B.S. in Chemistry from Boston College and a Ph.D. in Organic Chemistry from Harvard University. He conducted postdoctoral studies at the Memorial Sloan-Kettering Cancer Center.

Michael Aceti

Michael Aceti is Head of Finance at Blend, with 10 years of experience in the biotechnology industry. Most recently, he was Senior Director at Genzyme, where he held roles in finance and commercial operations. Prior to Genzyme, Mr. Aceti was CFO of Innosight, a consulting firm founded by Harvard Business School Professor and author Clayton Christensen, as well as Vice President of Finance at GenRad. He received a B.A. in Economics at Saint Lawrence University and an M.B.A. in Finance and Strategy at the University of Chicago.